Angiogenesis
Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma
Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…
Read MoreRedefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
EBiomedicine 2019 October [Link] Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C,…
Read MoreExosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication.
Cancer Letters 2019 August 7 [Link] Monaco F, Gaetani S, Alessandrini F, Tagliabracci A, Bracci M, Valentino M, Neuzil J, Amati M, Bovenzi M, Tomasetti M, Santarelli L Abstract MiR-126 has been shown to suppress malignant mesothelioma (MM) by targeting cancer-related genes without inducing toxicity or histopathological changes. Exosomes provide the opportunity to deliver therapeutic…
Read MoreInhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
Biochemical and Biophysical Research Communications 2019 March 5 [Link] Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE Abstract Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the…
Read MoreBrain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Molecular Cancer 2018 October 11 [Link] Smeele P, d’Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery…
Read MoreRole of angiopoietins in mesothelioma progression.
Cytokine 2018 September 7 [Link] Magkouta S, Kollintza A, Moschos C, Spella M, Skianis I, Pappas A, Vazakidou ME, Stathopoulos G, Kalomenidis I Abstract BACKGROUND AND OBJECTIVE: Anti-angiogenic treatment has been recently shown to be clinically beneficial for mesothelioma patients. Angiopoietins-1 and -2 are key regulators of tumor angiogenesis. Ang-1 is mainly known to promote…
Read MoreTargeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.
Oncotarget 2018 April 24 [Link] Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, Gorgoulis VG, Kalomenidis I Abstract Malignant pleural mesothelioma is resistant to currently used treatment. Angiopoieitn-1 directly promotes mesothelioma cell growth in a Tie-2-dependent fashion. Angiopoietin/Tie-2 axis may thus be valid targets for therapeutic interventions against mesothelioma.…
Read MoreAminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
The European Respiratory Journal [Epub ahead of print] [Link] Otsuki T et. al. Abstract Angiogenesis is a crucial factor in the progression of malignant pleural mesothelioma (MPM), and antiangiogenic strategies might be effective against MPM. Aminopeptidase N/CD13 (APN/CD13) promotes tumour angiogenesis and is associated with poor prognosis; however, its clinical significance in MPM remains unclear.In…
Read MoreHeterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications
International Journal of Molecular Science 2018 January 13 [Link] Tolani B, Acevedo LA, Hoang NT, He B Abstract Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most patients only survive for 5-12 months; irrespective of stage; after primary symptoms appear. Compounding matters is that MPM remains unresponsive to conventional standards of care; including radiation…
Read MoreComplement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth
Frontiers in Immunology 2017 November [Link] Agostinis C et. al. Abstract C1q is the first recognition subcomponent of the complement classical pathway, which acts toward the clearance of pathogens and apoptotic cells. C1q is also known to modulate a range of functions of immune and non-immune cells, and has been shown to be involved in…
Read More